Vaccines Market by Type, Vaccine Combination, Disease Indication, Vaccine Classification, Route of Administration, Dosage, Age Group, End User

The Vaccines Market is projected to reach USD 97.14 Billion in 2026. It is expected to continue growing at a CAGR of 7.76%, reaching USD 152.31 Billion by 2032.

Vaccines remain one of the highest-impact health technologies, preventing an estimated 3.5 million to 5 million deaths every year, according to the World Health Organization. The vaccines landscape spans pediatric immunization, adult boosters, travel vaccines, maternal vaccination, therapeutic cancer vaccines, and epidemic preparedness, creating a broad industry shaped by public procurement, private innovation, and global health security needs.

Demand is being driven by routine immunization recovery after COVID-19 disruptions, rising use of newer platforms such as mRNA, viral vectors, recombinant proteins, and conjugate technologies, expanded human papillomavirus and pneumococcal programs, and stronger government stockpiling for pandemic and outbreak response. WHO and UNICEF estimates also show persistent access gaps, including 14.5 million zero-dose children in 2023, making coverage recovery and equitable delivery central to long-term vaccine strategy. For industry leaders, success depends on evidence-based portfolio prioritization, resilient supply chains, regulatory agility, and access models that improve immunization coverage while sustaining commercial performance.

Transformative Shifts in the Vaccines Landscape

The vaccine industry is shifting from a primarily pediatric and seasonal business toward a life-course immunization model. Aging populations are increasing demand for influenza, pneumococcal, shingles, respiratory syncytial virus, and COVID-19 vaccines, while maternal immunization is gaining policy support as a way to protect infants before they are eligible for direct vaccination.

Technology is also reshaping competition. mRNA platforms demonstrated global scalability during the COVID-19 response, and developers are now applying nucleic acid, recombinant protein, conjugate, viral-vector, and combination approaches to influenza, RSV, oncology, and emerging infectious disease vaccines. At the same time, governments are emphasizing domestic manufacturing, fill-finish capacity, cold-chain resilience, genomic surveillance, and faster regulatory pathways to reduce dependence on concentrated supply hubs and strengthen epidemic readiness.

Cumulative Impact of Artificial Intelligence on Vaccines

Artificial intelligence is becoming a practical accelerator across vaccine discovery, clinical development, manufacturing, and pharmacovigilance. AI-enabled antigen design, protein structure modeling, epitope prediction, and immune-response simulation can help narrow candidate selection before costly trials. In clinical operations, analytics can improve site selection, participant recruitment, protocol optimization, and real-time safety monitoring.

The cumulative impact is faster cycle times and more targeted investment decisions, but responsible adoption is essential. Vaccine developers must validate AI outputs against laboratory and clinical evidence, protect patient data, reduce model bias, and maintain transparent regulatory documentation. Used well, AI can strengthen pandemic readiness, optimize strain selection, improve demand forecasting, enhance quality control, and improve post-market signal detection without replacing established scientific and regulatory standards.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is central to vaccine growth because of its population scale, expanding middle class, large birth cohorts, and manufacturing depth in China, India, Japan, South Korea, and Australia. The region is also shaped by high infectious-disease surveillance needs, national immunization expansion, and public investment in biotechnology capacity. North America remains a leading innovation and commercialization hub, supported by the U.S. biomedical research ecosystem, advanced regulatory pathways, robust adult immunization infrastructure, and coordinated public-health guidance in the United States and Canada.

Latin America shows rising demand for pediatric, HPV, influenza, dengue, and outbreak-response vaccines, with Brazil and Mexico anchoring public immunization programs and regional manufacturing ambitions. Europe combines mature vaccination programs with strong regulatory oversight through the European Medicines Agency and national technical advisory groups, while also prioritizing adult immunization, pharmacovigilance, antimicrobial-resistance prevention through vaccination, and supply resilience following pandemic-era procurement lessons.

The Middle East is investing in health security, procurement modernization, digital immunization systems, and domestic biologics capacity, particularly across high-income Gulf markets that are expanding preventive care and travel-related vaccination infrastructure. Africa represents both an urgent coverage opportunity and a long-term manufacturing priority, as the African Union and Africa CDC support expanded local vaccine production, stronger cold-chain systems, improved last-mile delivery, and more resilient supply networks to reduce dependence on imported vaccines.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are expanding vaccine demand through sizable birth cohorts, school-based immunization programs, travel recovery, dengue prevention priorities, and stronger pandemic preparedness, while regional procurement approaches still vary widely by country income, financing structures, and health system capacity. The GCC is prioritizing immunization modernization, digital health records, life-course vaccination, and strategic purchasing, creating opportunities for adult vaccines, travel vaccines, and public-private supply partnerships.

The European Union remains influential through centralized regulatory standards, joint procurement experience, pharmacovigilance coordination, and health security planning under regional preparedness frameworks. BRICS economies combine large population needs with growing domestic manufacturing, public-sector procurement, and technology-transfer priorities, making them important for high-volume immunization delivery, localized production, and diversified global vaccine supply.

G7 countries lead in vaccine R&D financing, regulatory science, premium-market adoption, and preparedness funding, especially for adult, maternal, respiratory, and specialty vaccines. NATO members increasingly view vaccine availability as part of biodefense, military readiness, force health protection, and civil resilience, reinforcing the link between immunization, emergency preparedness, and national security.

Key Country Insights Across Major Vaccine Markets

The United States leads global vaccine innovation through deep capital markets, NIH-supported research, BARDA preparedness funding, ACIP guidance, and large commercial and public immunization channels. Canada emphasizes public procurement, national immunization guidance, and equitable access across provinces and territories, while Mexico combines public-sector demand with regional manufacturing potential and cross-border disease surveillance priorities. Brazil is a major Latin American anchor through its National Immunization Program, large public-sector purchasing role, and established public vaccine production capabilities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature vaccine markets with strong regulatory systems, adult immunization needs, public purchasing mechanisms, and established pharmacovigilance practices. The United Kingdom has a prominent national immunization advisory structure and clinical research capacity; Germany and France bring advanced biomedical ecosystems and strong public-health infrastructure; Italy and Spain continue to focus on pediatric, elderly, and regional coverage improvements. Russia maintains domestic vaccine capabilities and sovereign supply priorities. China and India are critical to global scale: China has a large domestic immunization base and expanding biotechnology capabilities, while India is one of the world’s largest vaccine suppliers by volume and a key source for routine immunization programs in low- and middle-income countries.

Japan, Australia, and South Korea are high-value Asia-Pacific vaccine markets with strong quality standards, aging populations, and active life-science ecosystems. Japan’s demographic profile supports demand for adult and elderly immunization, Australia is important for seasonal influenza surveillance and regional public-health preparedness, and South Korea is strengthening its role in advanced biomanufacturing, clinical research, and regional epidemic-response partnerships.

Actionable Recommendations for Vaccine Industry Leaders

Industry leaders should prioritize life-course immunization portfolios, including adult respiratory, maternal, adolescent, travel, and specialty vaccines, while protecting core pediatric franchises. Commercial plans should be aligned with national immunization technical advisory group evidence requirements, real-world effectiveness data, safety monitoring, and health-economic models that demonstrate avoided hospitalizations, productivity gains, and health-system savings.

Operationally, organizations should diversify antigen, adjuvant, vial, stopper, lipid nanoparticle, cold-chain, and fill-finish supply; build regional manufacturing partnerships; and invest in end-to-end supply visibility. Leaders should also embed AI governance, strengthen pharmacovigilance, support vaccine confidence campaigns, improve healthcare-provider education, and design access models for low- and middle-income countries through tiered pricing, pooled procurement, donation mechanisms, and technology transfer where appropriate.

Research Methodology

This executive summary is based on a structured review of verified public-health, regulatory, and industry evidence. Core sources include the World Health Organization, UNICEF, Gavi, the Vaccine Alliance, the U.S. Centers for Disease Control and Prevention, the European Medicines Agency, national immunization programs, public procurement documents, peer-reviewed literature, and publicly available government and institutional disclosures.

The analysis combines disease-burden trends, immunization coverage data, technology-platform developments, regulatory patterns, procurement dynamics, cold-chain requirements, and regional manufacturing priorities. Findings were synthesized to identify durable strategic themes rather than short-term fluctuations, with emphasis on evidence that is internationally recognized, reproducible, and relevant to vaccine developers, manufacturers, distributors, healthcare providers, policymakers, and investors.

Conclusion

The vaccines sector is entering a more complex but opportunity-rich phase. Routine immunization recovery, adult vaccine expansion, mRNA and recombinant-platform innovation, AI-assisted development, and health-security investment are reshaping how vaccines are discovered, manufactured, financed, regulated, and delivered.

Winning organizations will combine scientific excellence with access discipline. They will need to prove clinical value, scale reliably, navigate regional policy differences, and support public trust. As governments and healthcare systems continue to treat immunization as both preventive care and strategic preparedness, vaccines will remain central to global health outcomes and long-term life-science growth.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Vaccines Market, by Type

7.1. Inactivated Vaccines
7.2. Live-Attenuated Vaccines
7.3. Messenger RNA Vaccines
7.4. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
7.5. Toxoid Vaccines
7.6. Viral Vector Vaccines

8. Vaccines Market, by Vaccine Combination

8.1. Mono-Valent Vaccines
8.2. Multi-Valent Vaccines

9. Vaccines Market, by Disease Indication

9.1. Infectious Disease Vaccines
9.1.1. Influenza
9.1.2. Hepatitis A & B
9.1.3. Polio
9.1.4. COVID-19
9.1.5. Pneumococcal & Meningococcal Disease
9.1.6. Human Papillomavirus HPV
9.1.7. Rotavirus
9.1.8. Dengue
9.1.9. Malaria
9.1.10. Rabies
9.2. Non-Infectious Disease Vaccines
9.2.1. Cancer Vaccines
9.2.2. Allergy Vaccines
9.2.3. Alzheimer’s Vaccines

10. Vaccines Market, by Vaccine Classification

10.1. Preventive Vaccines
10.2. Therapeutic Vaccines

11. Vaccines Market, by Route of Administration

11.1. Intramuscular
11.2. Intranasal
11.3. Oral
11.4. Subcutaneous

12. Vaccines Market, by Dosage

12.1. Multi Dose
12.2. Single Dose

13. Vaccines Market, by Age Group

13.1. Adult
13.2. Geriatric
13.3. Pediatric
13.3.1. Infants
13.3.2. Toddlers

14. Vaccines Market, by End User

14.1. Academic & Research Institutes
14.2. Hospitals & Clinics
14.3. Vaccination Centers

15. Asia-Pacific Vaccines Market
16. Europe Vaccines Market
17. North America Vaccines Market
18. Latin America Vaccines Market
19. Africa Vaccines Market
20. Middle East Vaccines Market
21. NATO Vaccines Market
22. G7 Vaccines Market
23. European Union Vaccines Market
24. BRICS Vaccines Market
25. ASEAN Vaccines Market
26. GCC Vaccines Market
27. United States Vaccines Market
28. China Vaccines Market
29. Germany Vaccines Market
30. Japan Vaccines Market
31. India Vaccines Market
32. United Kingdom Vaccines Market
33. France Vaccines Market
34. Canada Vaccines Market
35. Italy Vaccines Market
36. Australia Vaccines Market
37. South Korea Vaccines Market
38. Brazil Vaccines Market
39. Mexico Vaccines Market
40. Russia Vaccines Market
41. Spain Vaccines Market

42. Competitive Landscape

42.1. Market Concentration Analysis, 2025
42.1.1. Concentration Ratio (CR)
42.1.2. Herfindahl Hirschman Index (HHI)
42.2. Recent Developments & Impact Analysis, 2025
42.3. Product Portfolio Analysis, 2025
42.4. Benchmarking Analysis, 2025

43. Company Profiles

43.1. Pfizer Inc.
43.2. BioNTech SE
43.3. Sinovac Biotech Ltd.
43.4. Moderna, Inc.
43.5. Merck & Co., Inc.
43.6. GlaxoSmithKline PLC
43.7. Sanofi S.A.
43.8. Johnson & Johnson Services, Inc.
43.9. AstraZeneca PLC
43.10. Abbott Laboratories
43.11. Astellas Pharma Inc.
43.12. Bavarian Nordic A/S
43.13. Bharat Biotech Ltd.
43.14. Biological E. Limited
43.15. Blue Lake Biotechnology
43.16. Capricor Therapeutics, Inc.
43.17. Chongqing Zhifei Biological Products Co., Ltd.
43.18. CSL Limited
43.19. CureVac N.V.
43.20. Daiichi Sankyo Company, Limited.
43.21. Gennova Biopharmaceuticals Limited
43.22. Haffkine Bio-Pharmaceutical Corporation Ltd.
43.23. Incepta Pharmaceuticals Ltd.
43.24. Inovio Pharmaceuticals, Inc.
43.25. Novavax, Inc.
43.26. Serum Institute of India Pvt. Ltd.
43.27. Takeda Pharmaceutical Company Limited
43.28. VBI Vaccines Inc.
43.29. Versatope Therapeutics
43.30. Zydus Lifesciences Limited

List of Figures

FIGURE 1. GLOBAL VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL VACCINES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL VACCINES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL VACCINES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2025 VS 2032 (%)
FIGURE 25. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 27. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 29. GLOBAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. ASIA-PACIFIC VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. ASIA-PACIFIC VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. NORTH AMERICA VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. NORTH AMERICA VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. LATIN AMERICA VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. LATIN AMERICA VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. AFRICA VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. AFRICA VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. MIDDLE EAST VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 41. MIDDLE EAST VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. NATO VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. NATO VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. G7 VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. G7 VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. EUROPEAN UNION VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. EUROPEAN UNION VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. BRICS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. BRICS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. ASEAN VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. ASEAN VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. GCC VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 53. GCC VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 54. UNITED STATES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. CHINA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. GERMANY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. JAPAN VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. INDIA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. UNITED KINGDOM VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. FRANCE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. CANADA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. ITALY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. AUSTRALIA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SOUTH KOREA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. BRAZIL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. MEXICO VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 67. RUSSIA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 68. SPAIN VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LIVE-ATTENUATED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LIVE-ATTENUATED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LIVE-ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MESSENGER RNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MESSENGER RNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MESSENGER RNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL TOXOID VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL TOXOID VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL TOXOID VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MONO-VALENT VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MONO-VALENT VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MONO-VALENT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MULTI-VALENT VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MULTI-VALENT VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MULTI-VALENT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL HEPATITIS A & B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL HEPATITIS A & B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL HEPATITIS A & B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL POLIO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL POLIO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL POLIO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL COVID-19 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL COVID-19 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL COVID-19 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PNEUMOCOCCAL & MENINGOCOCCAL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PNEUMOCOCCAL & MENINGOCOCCAL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PNEUMOCOCCAL & MENINGOCOCCAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL HUMAN PAPILLOMAVIRUS HPV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL HUMAN PAPILLOMAVIRUS HPV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL HUMAN PAPILLOMAVIRUS HPV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ROTAVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ROTAVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ROTAVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL DENGUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL DENGUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL DENGUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MALARIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MALARIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MALARIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL RABIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL RABIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL RABIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NON-INFECTIOUS DISEASE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NON-INFECTIOUS DISEASE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NON-INFECTIOUS DISEASE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ALLERGY VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ALLERGY VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ALLERGY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ALZHEIMER’S VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ALZHEIMER’S VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ALZHEIMER’S VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL INTRANASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL INTRANASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL INTRANASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL MULTI DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL MULTI DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL MULTI DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL SINGLE DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL SINGLE DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL SINGLE DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL INFANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL INFANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL INFANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL TODDLERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL TODDLERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL TODDLERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL VACCINATION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL VACCINATION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL VACCINATION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. EUROPE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 146. EUROPE VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 147. EUROPE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 148. EUROPE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 149. EUROPE VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 150. EUROPE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 151. EUROPE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 152. EUROPE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153. EUROPE VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 154. EUROPE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 155. EUROPE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 156. EUROPE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. AFRICA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 182. AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 183. AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 184. AFRICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 185. AFRICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 186. AFRICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 187. AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 188. AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 189. AFRICA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 190. AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 191. AFRICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 192. AFRICA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 199. MIDDLE EAST VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. NATO VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 206. NATO VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 207. NATO VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 208. NATO VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 209. NATO VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 210. NATO VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 211. NATO VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 212. NATO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. NATO VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 214. NATO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 215. NATO VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 216. NATO VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. G7 VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 218. G7 VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 219. G7 VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 220. G7 VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 221. G7 VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 222. G7 VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 223. G7 VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 224. G7 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 225. G7 VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 226. G7 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 227. G7 VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 228. G7 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. BRICS VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 242. BRICS VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 243. BRICS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 244. BRICS VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 245. BRICS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 246. BRICS VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 247. BRICS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 248. BRICS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. BRICS VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 250. BRICS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 251. BRICS VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 252. BRICS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 253. ASEAN VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 254. ASEAN VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 255. ASEAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 256. ASEAN VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 257. ASEAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 258. ASEAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 259. ASEAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 260. ASEAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 261. ASEAN VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 262. ASEAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 263. ASEAN VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 264. ASEAN VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 265. GCC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 266. GCC VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 267. GCC VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 268. GCC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 269. GCC VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 270. GCC VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 271. GCC VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 272. GCC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 273. GCC VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 274. GCC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 275. GCC VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 276. GCC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 277. UNITED STATES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 278. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 279. UNITED STATES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 280. UNITED STATES VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 281. UNITED STATES VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 282. UNITED STATES VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 283. UNITED STATES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 284. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 285. UNITED STATES VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 286. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 287. UNITED STATES VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 288. UNITED STATES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 289. CHINA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 290. CHINA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 291. CHINA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 292. CHINA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 293. CHINA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 294. CHINA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 295. CHINA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 296. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 297. CHINA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 298. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 299. CHINA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 300. CHINA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 301. GERMANY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 302. GERMANY VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 303. GERMANY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 304. GERMANY VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 305. GERMANY VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 306. GERMANY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 307. GERMANY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 308. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 309. GERMANY VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 310. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 311. GERMANY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 312. GERMANY VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 313. JAPAN VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 314. JAPAN VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 315. JAPAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 316. JAPAN VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 317. JAPAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 318. JAPAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 319. JAPAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 320. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 321. JAPAN VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 322. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 323. JAPAN VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 324. JAPAN VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 325. INDIA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 326. INDIA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 327. INDIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 328. INDIA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 329. INDIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 330. INDIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 331. INDIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 332. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 333. INDIA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 334. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 335. INDIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 336. INDIA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 337. UNITED KINGDOM VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 338. UNITED KINGDOM VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 339. UNITED KINGDOM VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 340. UNITED KINGDOM VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 341. UNITED KINGDOM VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 342. UNITED KINGDOM VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 343. UNITED KINGDOM VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 344. UNITED KINGDOM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 345. UNITED KINGDOM VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 346. UNITED KINGDOM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 347. UNITED KINGDOM VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 348. UNITED KINGDOM VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 349. FRANCE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 350. FRANCE VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 351. FRANCE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 352. FRANCE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 353. FRANCE VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 354. FRANCE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 355. FRANCE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 356. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 357. FRANCE VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 358. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 359. FRANCE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 360. FRANCE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 361. CANADA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 362. CANADA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 363. CANADA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 364. CANADA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 365. CANADA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 366. CANADA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 367. CANADA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 368. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 369. CANADA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 370. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 371. CANADA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 372. CANADA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 373. ITALY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 374. ITALY VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 375. ITALY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 376. ITALY VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 377. ITALY VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 378. ITALY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 379. ITALY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
TABLE 380. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 381. ITALY VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
TABLE 382. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 383. ITALY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 384. ITALY VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 385. AUSTRALIA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 386. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 387. AUSTRALIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
TABLE 388. AUSTRALIA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 389. AUSTRALIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
TABLE 390. AUSTRALIA VACCINES

Companies Mentioned

The companies featured in this Vaccines market report include:

Pfizer Inc.
BioNTech SE
Sinovac Biotech Ltd.
Moderna, Inc.
Merck & Co., Inc.
GlaxoSmithKline PLC
Sanofi S.A.
Johnson & Johnson Services, Inc.
AstraZeneca PLC
Abbott Laboratories
Astellas Pharma Inc.
Bavarian Nordic A/S
Bharat Biotech Ltd.
Biological E. Limited
Blue Lake Biotechnology
Capricor Therapeutics, Inc.
Chongqing Zhifei Biological Products Co., Ltd.
CSL Limited
CureVac N.V.
Daiichi Sankyo Company, Limited.
Gennova Biopharmaceuticals Limited
Haffkine Bio-Pharmaceutical Corporation Ltd.
Incepta Pharmaceuticals Ltd.
Inovio Pharmaceuticals, Inc.
Novavax, Inc.
Serum Institute of India Pvt. Ltd.
Takeda Pharmaceutical Company Limited
VBI Vaccines Inc.
Versatope Therapeutics
Zydus Lifesciences Limited

Table Information

Report Attribute	Details
No. of Pages	197
Published	June 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 97.14 Billion
Forecasted Market Value ( USD ) by 2032	$ 152.31 Billion
Compound Annual Growth Rate	7.7%
Regions Covered	Global
No. of Companies Mentioned	31

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3211EUR$3,545USD£2,770GBP €3568EUR$3,939USD£3,078GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4858EUR$5,363USD£4,191GBP €5398EUR$5,959USD£4,657GBP

Vaccines Market by Type, Vaccine Combination, Disease Indication, Vaccine Classification, Route of Administration, Dosage, Age Group, End User - Global Forecast 2026-2032

Transformative Shifts in the Vaccines Landscape

Cumulative Impact of Artificial Intelligence on Vaccines

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Key Country Insights Across Major Vaccine Markets

Actionable Recommendations for Vaccine Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Transformative Shifts in the Vaccines Landscape

Cumulative Impact of Artificial Intelligence on Vaccines

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Key Country Insights Across Major Vaccine Markets

Actionable Recommendations for Vaccine Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Vaccines - Market Insights, Competitive Landscape, and Market Forecast - 2030

United States Vaccine Market Report and Forecast 2024-2032

North America Vaccines Market Outlook, 2028

Vaccine Management Solutions - Global Strategic Business Report

Pneumococcal 13-valent Conjugate Vaccine Market - Global Forecast 2026-2032